BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:05 2024-04-23 pm EDT			5-day change	1st Jan Change
4.375 ^USD	-0.79%		-5.10%	-26.96%

Apr. 17	BioCryst Pharmaceuticals Secures Approval for Orladeyo in Brazil	MT
Apr. 17	BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency	CI

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

November 01, 2022 at 07:06 am EDT

BioCryst Pharmaceuticals, Inc. provided earnings guidance for the year 2022. Based on the strength of the ORLADEYO launch through the first three quarters of 2022, the company expects full year 2022 net ORLADEYO revenue to be $255 million.

Latest news about BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals Secures Approval for Orladeyo in Brazil	Apr. 17	MT
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency	Apr. 17	CI
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM	Mar. 12
Transcript : BioCryst Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows as Revenue Increases	Feb. 26	MT
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Posts Q4 Revenue $93.4M, vs. Street Est of $90M	Feb. 26	MT
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024	Feb. 26	CI
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
North American Morning Briefing : Traders Await Inflation Data This Week	Feb. 26	DJ
BioCryst Launches Hereditary Angioedema Drug in Italy	Feb. 20	MT
BioCryst Launches Orladeyo (Berotralstat) in Italy	Feb. 19	CI
Transcript : BioCryst Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:00 PM	Jan. 09
BioCryst Pharmaceuticals Sees FY23, FY24 Orladeyo Sales Topping Prior Forecast; Eyes 2024 Operating Profit	Jan. 05	MT
BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Jan. 05	CI
BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)	Dec. 19	CI
Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023	Dec. 01	CI
BioCryst Amends Deal With Torii Pharmaceutical for Orladeyo's Commercialization in Japan; Shares Rise	Nov. 30	MT
BioCryst Pharmaceuticals Receives Argentine Regulatory Approval for Orladeyo	Nov. 29	MT
Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina	Nov. 29	CI
BioCryst Pharmaceuticals Says Hereditary Angioedema Treatment Gets Marketing Authorization in Spain	Nov. 21	MT
BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO	Nov. 21	CI
BioCryst Says Trial Data Show Treatment With Orladeyo Leads to Reduction of Hereditary Angioedema Attacks	Nov. 10	MT
BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat)	Nov. 10	CI
BioCryst Pharmaceuticals, Clearside Biomedical Enter Drug Development Collaboration	Nov. 03	MT

Chart BioCryst Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for BioCryst Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.41 USD

Average target price

12.2 USD

Spread / Average Target

+176.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOCRYST PHARMACEUTICALS, INC.	-26.96%	903M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+1.66%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-6.82%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs